TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia-Reference-Cited by-同舟云学术

TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia

Published:2018-06-21 Issue:25 Volume:131 Page:2803-2815
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Yang Jun¹,LeBlanc Francis R.¹²^ORCID,Dighe Shubha A.¹,Hamele Cait E.¹,Olson Thomas L.¹^ORCID,Feith David J.¹^ORCID,Loughran Thomas P.¹

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, University of Virginia Cancer Center, University of Virginia, Charlottesville, VA; and

2. Penn State College of Medicine, Hershey, PA

Abstract

Key Points TRAIL is upregulated in LGL leukemia and TRAIL-DcR2 signaling drives constitutive activation of NF-κB. Proteasome inhibitors (bortezomib and ixazomib) effectively interrupt TRAIL-induced activation of NF-κB and induce apoptosis.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/25/2803/1466127/blood808816.pdf

Reference48 articles.

1. Clonal diseases of large granular lymphocytes;Loughran;Blood,1993

2. How I treat LGL leukemia;Lamy;Blood,2011

3. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia;Yang;Blood,2008

4. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia;Jerez;Blood,2012

5. Somatic STAT3 mutations in large granular lymphocytic leukemia;Koskela;N Engl J Med,2012

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blocking the TRAIL-DR5 Pathway Reduces Cardiac Ischemia–Reperfusion Injury by Decreasing Neutrophil Infiltration and Neutrophil Extracellular Traps Formation;Cardiovascular Drugs and Therapy;2024-06-20

2. Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment;Cancers;2024-03-27

3. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors;Cell Communication and Signaling;2024-02-08

4. Increased Expression of TRAIL and Its Death Receptors TRAIL-R1/2 Correlates with Progression of Radioactive Skin Injury;J BIOL REG HOMEOS AG;2024

5. Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia;Blood;2023-10-12